Scholarlink

<p>Surface-enhanced Raman spectroscopy (SERS) has been employed in the current study to characterize various ovarian cancer stages using blood serum samples from both healthy controls and clinically recognized ovarian cancer patients. The SERS spectral features acquired using the SERS technique from these blood serum samples are compared to identify spectral characteristics that can be used for the identification and classification of ovarian cancer samples. Principal component analysis (PCA) is performed on the SERS spectral data sets obtained from blood serum samples of clinically confirmed patients of stage IV, stage III, and stage II of ovarian cancer, as well as from control samples, in order to investigate the potential of SERS as an effective tool for analysis that can explain how ovarian cancer progresses. SERS can be used for screening and early identification of biochemical changes occurring due to the progression of ovarian cancer reflected in the form of characteristic SERS spectral features of these samples.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Surface-Enhanced Raman Spectroscopy (SERS) for the Characterization of the Blood Serum Samples of Ovarian Cancer

  • 期刊论文

  • 发表日期：

    2025年5月6日

查看全文
  • Saima Aziz,
  • Noor ul Huda,
  • Haq Nawaz,
  • Muhammad Irfan Majeed,
  • Abdulrahman Alshammari,
  • Norah A. Albekairi,
  • Muhammad Zeshan Khalil,
  • Hira Shafique,
  • Habiba Shahid,
  • Iqra Yaseen,
  • Mariam Shakeel,
  • Imran Amin

摘要

Surface-enhanced Raman spectroscopy (SERS) has been employed in the current study to characterize various ovarian cancer stages using blood serum samples from both healthy controls and clinically recognized ovarian cancer patients. The SERS spectral features acquired using the SERS technique from these blood serum samples are compared to identify spectral characteristics that can be used for the identification and classification of ovarian cancer samples. Principal component analysis (PCA) is performed on the SERS spectral data sets obtained from blood serum samples of clinically confirmed patients of stage IV, stage III, and stage II of ovarian cancer, as well as from control samples, in order to investigate the potential of SERS as an effective tool for analysis that can explain how ovarian cancer progresses. SERS can be used for screening and early identification of biochemical changes occurring due to the progression of ovarian cancer reflected in the form of characteristic SERS spectral features of these samples.